Samsung BioLogics moves into the green in 2017Samsung BioLogics, a biopharmaceutical unit of Korea’s top conglomerate, Samsung Group, posted an operating income last year, shifting from a loss a year earlier, the company said Wednesday.
The total reached 63 billion won ($60 million) in 2017, compared to a 30.4 billion won loss reported a year earlier, the company said in a regulatory filing.
Sales also jumped 56.1 percent on-year to 459.8 billion won for the whole of last year, the company said.
Samsung BioLogics manufactures products for pharmaceutical brands such as Bristol-Myers Squibb and Roche Holding.
More in Industry
DSME fined ￦15.3 billion for mistreating subcontractors
Hyundai, Naver to work together on connected car systems
SK Telcom merges two security services subsidiaries
KDB requests sit-down with Asiana unions about takeover
Are you Taycan to me?